HADHA Human shRNA Lentiviral Particle (Locus ID 3030)
CAT#: TL312528V
HADHA - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
Need custom lentivirus service?
Get a free quote
CNY 11,400.00
Cited in 1 publication. |
Product images
CNY 2,950.00
CNY 1,999.00
CNY 2,700.00
Specifications
Product Data | |
Product Name | HADHA Human shRNA Lentiviral Particle (Locus ID 3030) |
Locus ID | 3030 |
Synonyms | ECHA; GBP; HADH; LCEH; LCHAD; MTPA; TP-ALPHA |
Vector | pGFP-C-shLenti |
Format | Lentiviral particles |
RefSeq | NM_000182, NM_000182.1, NM_000182.2, NM_000182.3, NM_000182.4, BC009235, BC009235.2, NM_000182.5 |
Summary | This gene encodes the alpha subunit of the mitochondrial trifunctional protein, which catalyzes the last three steps of mitochondrial beta-oxidation of long chain fatty acids. The mitochondrial membrane-bound heterocomplex is composed of four alpha and four beta subunits, with the alpha subunit catalyzing the 3-hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase activities. Mutations in this gene result in trifunctional protein deficiency or LCHAD deficiency. The genes of the alpha and beta subunits of the mitochondrial trifunctional protein are located adjacent to each other in the human genome in a head-to-head orientation. [provided by RefSeq, Jul 2008] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
Targeting the mitochondrial trifunctional protein restrains tumor growth in oxidative lung carcinomas
,Amoedo, ND;Sarlak, S;Obre, E;Esteves, P;Bégueret, H;Kieffer, Y;Rousseau, B;Dupis, A;Izotte, J;Bellance, N;Dard, L;Redonnet-Vernhet, I;Punzi, G;Rodrigues, MF;Dumon, E;Mafhouf, W;Guyonnet-Dupérat, V;Gales, L;Palama, T;Bellvert, F;Dugot-Senan, N;Claverol, S;Baste, JM;Lacombe, D;Rezvani, HR;Pierri, CL;Mechta-Grigoriou, F;Thumerel, M;Rossignol, R;,
The Journal of clinical investigation
,PubMed ID 33393495
[HADHA]
|
Documents
Product Manuals |
FAQs |
SDS |